NBP
NASDAQNovaBridge Biosciences
News25/Ratings1
News · 26 weeks59+29%
2026-01-252026-07-19
Mix2390d
- Insider12(52%)
- SEC Filings5(22%)
- Other4(17%)
- Leadership2(9%)
Latest news
25 items- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Hagler Mark Arnold4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel Lin Liwei Lorraine4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Gupta Srishti4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gupta Srishti3 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSVP, Clinical Development Xu Cong Claire converted options into 12,432 units of Ordinary Shares and sold $3,992 worth of Ordinary Shares (4,485 units at $0.89), increasing direct ownership by 3% to 298,101 units (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 4 filed by Director Fu Wei4 - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive OfficerROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) ("NovaBridge" or the "Company"), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition. Dr. Gupta is an experienced CEO who brings more than two decades of transformative leadership across biopharmaceuticals, global he
- INSIDERSEC Form 4 filed by Chief Bus. Development Officer Cao Sean Wuxiong4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERChief Medical Officer Dennis Phillip Andrew converted options into 23,695 units of Ordinary Shares and sold $5,606 worth of Ordinary Shares (8,494 units at $0.66), increasing direct ownership by 11% to 157,941 units (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- SECAmendment: SEC Form 20-F/A filed by NovaBridge Biosciences20-F/A - NovaBridge Biosciences (0001778016) (Filer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric CancerRegistrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to givastomig in combination with nivolumab and chemotherapy for the treatment of patients with previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas (GEA)
- INSIDERSVP, Clinical Development Xu Cong Claire converted options into 9,382 units of Ordinary Shares and sold $13,766 worth of Ordinary Shares (3,494 units at $3.94), increasing direct ownership by 2% to 290,154 units (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- PRNovaBridge to Present at the 2026 Jefferies Global Healthcare ConferenceROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company's senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026. Conference details are as follows: 2026 Jefferies Global Healthcare ConferenceFormat: Company Presentation and one-on-one investor meetingsDate: Thursday, June 4, 2026Presentation time: 3:10 PM ET Webcast Link: Here The webcast of the Jefferies presentation will be accessible on th
- INSIDEROfficer Cao Sean Wuxiong sold $42,584 worth of Ordinary Shares (21,399 units at $1.99), decreasing direct ownership by 38% to 35,073 units (SEC Form 4) to cover taxes4 - NovaBridge Biosciences (0001778016) (Issuer)
- PRNovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of NovaBridge's management team will participate in the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference being held on May 19, 2026. Conference details are as follows: H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat: Fireside Chat Date: Tuesday, May 19, 2026Time: 3:30 PM ETWebcast Link: Here The webcast of the company presentation will be accessible on the News & Events page of th
- INSIDEROfficer Hagler Mark Arnold bought $577,300 worth of Ordinary Shares (230,000 units at $2.51) (SEC Form 4)4 - NovaBridge Biosciences (0001778016) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hagler Mark Arnold3 - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
- PRNovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline ValueSeasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussionsStrong industry reputation and commercial track record in high-value pharmaceutical markets including oncology and ophthalmologyStrengthens NovaBridge's leadership team as the Company advances givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific antibody for first line (1L) gastric cancer, toward registrational pivotal studies and continues to advance VIS-101, purpose-designed, potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- NovaBridge Bioscienc
- INSIDERAmendment: SEC Form 3 filed by new insider Xu Cong Claire3/A - NovaBridge Biosciences (0001778016) (Issuer)
- SECSEC Form 6-K filed by NovaBridge Biosciences6-K - NovaBridge Biosciences (0001778016) (Filer)
NBP FAQ
6 questionsWhere does NBP stock trade?
NovaBridge Biosciences (NBP) is listed on NASDAQ.What sector and industry is NBP in?
NovaBridge Biosciences operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NovaBridge Biosciences go public?
NovaBridge Biosciences (NBP) completed its IPO in 2020.What are analysts saying about NBP?
NovaBridge Biosciences has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2026-02-06. Recent price targets cluster around $900.00.What companies are similar to NBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NBP side-by-side with any of them on Quantisnow.How can I track NBP on Quantisnow?
Quantisnow aggregates NovaBridge Biosciences's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NBP to receive live email and push alerts on every new disclosure.